Finance

Beta
Lists
QTTB:NASDAQ
Q32 Bio Inc
$13.62
+5.87%
(+0.76) 1D
$13.62
0.00% (0.00)
After hours
Closed: Jul 7, 4:00:00 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for QTTB...
Open
$13.48
High
$14.20
Low
$12.66
Mkt. cap
230.86M
Avg. vol.
1.23M
Volume
0.00
P/E ratio
5.14
52-wk high
$15.02
52-wk low
$1.35
EPS
$2.65
Beta
0.24
Shares outstanding
23.68M
No. of employees
22
Open
$13.48
High
$14.20
Low
$12.66
Mkt. cap
230.86M
Avg. vol.
1.23M
Volume
0.00
P/E ratio
5.14
52-wk high
$15.02
52-wk low
$1.35
EPS
$2.65
Beta
0.24
Shares outstanding
23.68M
No. of employees
22
News stories
From sources across the web
About Q32 Bio Inc
CEO-
Employees22
Founded2017
HeadquartersWaltham, Massachusetts, United States
SectorBiotechnology
Websiteq32bio.com
Analyst ratings
Based on 4 analysts giving stock ratings to QTTB in the past 3 months
Strong buy
Buy
3
Hold
1
Sell
0
12-month forecast
Based on 4 Wall Street analysts offering 12 month price targets for QTTB in the last 3 months.
Highest
Current $13.62
$14.00 (+2.79%)
Average
$12.33 (-9.47%)
Lowest
$10.00 (-26.58%)
Analyst
Recommendation
Action
Price target
Projected
Date
Richard Poland
Wells Fargo
Hold
Maintained
$10.00
-26.6%
05/28/2026
Unknown Analyst
Wells Fargo
Hold
Maintained
$10.00
-26.6%
05/28/2026
Joseph Catanzaro
Mizuho Securities
Buy
Initiated
$14.00
+2.8%
05/22/2026
Unknown Analyst
Cantor Fitzgerald
Buy
Initiated
-
-
05/18/2026
Imogen Mansfield
Cantor Fitzgerald
Buy
Initiated
-
-
05/18/2026
Imogen Mansfield
Cantor Fitzgerald
Buy
Initiated
-
-
05/18/2026
Joseph Pantginis
H.C. Wainwright
Buy
Reiterated
$13.00
-4.6%
05/05/2026
Jay Olson
Oppenheimer
Buy
Maintained
$20.00
+46.8%
03/11/2026
Derek Archila
Wells Fargo
Hold
Maintained
$10.00
-26.6%
03/11/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
-
-
53.74M
-
Cost of goods sold
280.00K
3.56M
3.32M
3.22M
Cost of revenue
280.00K
3.56M
3.32M
3.22M
Research and development expenses
4.88M
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
4.01M
4.02M
4.54M
4.50M
Operating expense
8.89M
4.02M
4.54M
4.50M
Total operating expenses
9.17M
7.58M
7.86M
7.72M
Operating income
-9.17M
-7.58M
45.88M
-7.72M
Other non operating income
-618.00K
-12.00K
-12.00K
-79.00K
EBT including unusual items
-9.49M
-7.39M
57.73M
-7.61M
EBT excluding unusual items
-9.49M
-7.39M
46.07M
-7.61M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-9.49M
-7.39M
57.73M
-7.61M
Net profit margin
-
-
107.43%
-
Earnings per share
-
-
-
-
Interest and investment income
600.00K
500.00K
400.00K
392.00K
Interest expense
-300.00K
-300.00K
-200.00K
-200.00K
Net interest expenses
300.00K
200.00K
200.00K
192.00K
Depreciation and amortization charges
-
-
-
-
EBITDA
-9.08M
-7.49M
45.97M
-7.63M
Gain or loss from assets sale
-
-
-11.74M
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

What's on your mind?
What's going on with the markets today?
Explore what’s possible
Create a task
Deep Search
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer